Elevance at 93.5% Claims Cost: Long-Term Winner or Margin Trap?

Elevance's Operating Strength Is Real-So Is the Claims Pressure

Investors are being asked to judge Elevance on two things at once: whether it is a durable health platform, or just a company working through a margin squeeze. The operating results still support the first case. Elevance reported first quarter adjusted EPS of $12.58 and later lifted its full-year adjusted EPS guidance to at least $27.00. But the claims picture keeps the debate alive. In Q4 2025, its benefit expense ratio rose to 93.5%, a reminder that medical cost pressure can quickly challenge the earnings story.

Q1 progress looks genuine, but it is not a clean proof point

The bullish read is straightforward: rising guidance usually suggests management is seeing better demand and cost control. The caution is important too. Elevance's Q1 adjusted EPS included about $1.00 per share of non-recurring investment income, and outside analysis said the operating beat was closer to about $0.30 per share from better claims experience. In other words, the business appears to be stabilizing, but the headline EPS number is not the purest evidence of that improvement.

Medical Inflation Remains the Main Threat to Margins

The core issue is simple. Elevance's benefit expense ratio increased by 110 basis points to 93.5%, leaving just 6.5 cents of every premium dollar for expenses, profit, and cushion. When medical costs run hot, that is where the squeeze shows up.

The macro backdrop is still not helping

This does not look like an isolated quarter. National health spending reached $5.3 trillion in 2024 and represented 18.0% of GDP. Hospital expenditures grew 8.9%, physician and clinical services spending grew 8.1%, and prescription drug spending rose 7.9%. If care providers and drugs keep getting more expensive, health plans remain on the defensive.

Bulls argue that a high claims ratio can normalize as trends cool. Bears note that the backdrop is still difficult. Plans are bracing for their highest medical cost trend in nearly two decades, with commercial healthcare cost trend expected to reach 9% in 2027.

Managed-care design gives Elevance more levers than a simple payer

That is why the business model matters. In Medicaid, Elevance is not just collecting premiums and paying claims. More than 60 percent of Medicaid beneficiaries are enrolled in managed care plans, and Elevance argues that Medicaid managed care can help states manage costs. In theory, that gives the company more tools to influence care patterns, monitor utilization, and contain waste.

Whether those tools can outrun current cost pressures is the real test. Industry analysis ties the projected 9% trend to provider revenue-optimization tools, pharmacy spending, behavioral health utilization, and out-of-network payment disputes. If Elevance can show measurable utilization control through those pressures, the model works. If not, the 93.5% ratio looks less like a blip and more like a warning.

Scale and Carelon Give Elevance More Room to Act

The claims-pressure debate is fair. The next question is whether Elevance has a system for regaining some of that margin control.

The scale is easy to verify

The bull case starts with reach. Elevance reported a total medical membership of 45.4 million, while external descriptions of the company describe roughly 104 million consumers served. That kind of footprint can mean stronger provider leverage, more data for care management, and more room to spread technology and operating investments across a large base.

Carelon and cost-management tools are the strategic levers

Management says it is accelerating investment in medical cost management, member and provider experience, operating efficiency, and Carelon's value-based solutions. Investors should view those investments through one simple lens: do they eventually reduce expensive utilization and improve consistency? If they do, the platform starts to look like a moat rather than just a cost center.

Medicare Advantage payment support helps, but it does not solve everything

CMS's CY 2026 MA payment increase of 5.06%, or more than $25 billion, gives Medicare Advantage operators a better pricing backdrop for next year. That helps, but it does not erase broader medical-cost pressure across other lines of business.

Why Elevance Still Looks More Like a Watch List Name Than a Clean Buy

Elevance still sits in the "maybe" bucket because the operating platform looks credible, while the margin recovery story still needs more proof.

Three reasons to stay selective

First, the Medicaid backdrop is getting tougher. Proposed federal changes would cut $911 billion in Medicaid spending over a decade and leave 7.5 million more people uninsured. That matters for a company described as heavily invested in Medicaid. Lower enrollment, payment strain, or slower state funding could weaken growth just as margins need room to recover.

Second, the cost environment is still hostile. Plans are bracing for the highest medical cost trend in nearly two decades, with commercial trend projected at 9% in 2027.

Third, recent improvement has some support, but not enough to close the book. Recent results were helped by favorable benefit expense performance, and guidance was raised to at least $27.00 in adjusted EPS. Investors still need to see that strength persist without a sudden easing in claims.

What would move the story from maybe to yes

Watch three signals together: whether the benefit expense ratio keeps improving, whether Medicaid pressure stabilizes, and whether investment in care management and Carelon starts to show up in more consistent quarterly results. If those signs strengthen together, the long-term bull case gets stronger. If they do not, the margin-trap argument stays relevant.